Spanish company is working on a new universal tuberculosis vaccine

Spanish company is developing a new universal tuberculosis vaccine

Spain's Biofabri company is completing the process of developing a new vaccine considered a turning point in the fight against tuberculosis. It is predicted that the preparation created by this enterprise based in the city of Vigo will radically change global methods of combating tuberculosis.

The main advantages of the developed vaccine are its universal nature, single-dose administration, and ease of storage. According to experts, these features will enable the widespread use of the preparation, especially in regions with limited medical supplies.

Researchers working on the project are trying to ensure that the vaccine is both affordable and highly effective. This strategy can contribute to significantly reducing the spread rate of tuberculosis in the global healthcare system.

Currently, the final phase of clinical trials is being carried out, and the results to be obtained are being followed with interest by the international community. With this initiative, Biofabri has managed to further strengthen Spain's position in the global fight against tuberculosis.